Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFC | NVO |
|---|---|---|
| Founded | 1852 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7B | 199.4B |
| IPO Year | 2020 | 2001 |
| Metric | WFC | NVO |
|---|---|---|
| Price | $82.55 | $38.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 14 |
| Target Price | ★ $97.48 | $45.80 |
| AVG Volume (30 Days) | ★ 11.9M | 8.5M |
| Earning Date | 10-13-2026 | 11-04-2026 |
| Dividend Yield | 2.41% | ★ 3.25% |
| EPS Growth | ★ 16.57 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | ★ $85,063,000,000.00 | N/A |
| Revenue This Year | $5.34 | N/A |
| Revenue Next Year | $5.42 | $1.28 |
| P/E Ratio | $23.09 | ★ $13.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $72.78 | $35.12 |
| 52 Week High | $97.76 | $64.16 |
| Indicator | WFC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 44.02 |
| Support Level | $77.95 | $38.02 |
| Resistance Level | $82.66 | $39.58 |
| Average True Range (ATR) | 1.94 | 0.65 |
| MACD | 0.30 | 0.38 |
| Stochastic Oscillator | 67.41 | 71.92 |
Wells Fargo is a premier, North American-focused banking titan that commands a $2.3 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,079 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.